Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

Impact · against what's priced in

Immunovant is viewed as a speculative buy based on the potentially best-in-class profile of IMVT-1402, particularly for Graves' disease. The analyst's $50 price target is underpinned by projected probability-adjusted peak sales of $4B.

IMVT+0.70

No priced-in read yet

In context

The initiation of coverage highlights IMVT-1402's strong IgG reduction with minimal albumin/LDL impact and a valuation based on $4B in probability-adjusted peak sales.

Read from the article alone

• pharmaceuticals▲2%
• biotech▲<1%
• equity research
• valuation
• IMVT
• drug pipeline
• graves disease

Top 2 movers · tap to explore